96 Tests PN: B112464


45x Ab-conjugated beads (S4P1 - Human 6Ckine Ab-bead). PN: B112464A. One vial containing 100 µL of anti-Human 6Ckine conjugated to AimPlex Bead S4P1

25x Biotin-detection Ab (Human 6Ckine Biotin-dAb). PN: B112464B. One vial containing 100 µL of biotinylated anti-Human 6Ckine.

Lyophilized Standard Mix-Human Group 6, Panel A, 7-Plex PN: HG61007. One vial containing lyophilized recombinant 6Ckine, BRAK, BCA-1, CTACK, CCL28, ENA-78, and CXCL16.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits

Application: Optimal antibody pair and antigen standard for assaying human 6Ckine. Can be multiplexed with other analytes in Human Group 6.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 6: Negligible

  • Sample volume: 15 µL/test


CCL21 (Chemokine C-C ligand 21) is a small cytokine belonging to the CC chemokine family. This chemokine is also known as 6Ckine (because it has six conserved cysteine residues instead of the four cysteines typical to chemokines), exodus-2, and secondary lymphoid-tissue chemokine (SLC).  CCL21 elicits its effects by binding to a cell surface chemokine receptor known as CCR7. Diseases associated with CCL21 include thymic hyperplasia and chronic inflammatory demyelinating polyradiculo-neuropathy.


  1. Hedrick JA, Zlotnik A (1997). "Identification and characterization of a novel beta chemokine containing six conserved cysteines". J. Immunol. 159 (4): 1589–93. PMID 9257816.

    Hromas R, Kim CH, Klemsz M, Krathwohl M, Fife K, Cooper S, Schnizlein-Bick C, Broxmeyer HE (1997). "Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension". J. Immunol. 159 (6): 2554–8. PMID 9300671.

  2. Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpää M, Takagi S, Nishimura M, Kakizaki M, Nomiyama H, Yoshie O (1997). "Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13". J. Biol. Chem. 272 (31): 19518–24. doi:10.1074/jbc.272.31.19518. PMID 9235955.